Modulating T regulatory cells in cancer: How close are we?

Immunology and Cell Biology

Volumn 91, Issue 5, 2013, Pages 340-349

  Banerjee, Ashish ^a   Vasanthakumar, Ajithkumar ^a,b   Grigoriadis, George ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c SOUTHERN HEALTH   (Australia)

Author keywords

cancer; immunotherapy; T regulatory cells

Indexed keywords

CARBONATE DEHYDRATASE IX; CELL SURFACE MARKER; CYCLOOXYGENASE 2; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNITY; BREAST CANCER; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL COUNT; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST; GENE EXPRESSION; HUMAN; HYPOXIA; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MELANOMA; MYELOBLAST; MYELOMA; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T CELL DEPLETION; THYMECTOMY; TRYPTOPHAN METABOLISM; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD4; AUTOIMMUNITY; CARCINOGENESIS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

MUS;

EID: 84878598816     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.12     Document Type: Review

References (133)

1. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969; 166: 753-755.
2. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J Exp Med 1982; 156: 1565-1576.
3. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161: 72-87.
4. Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J Immunol 1972; 108: 586-590
5. Powrie F, Mason D. OX-22high CD4- T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 1990; 172: 1701-1708
6. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4- Tcell subset that inhibits this autoimmune potential. J Exp Med 1993; 177: 627-636
7. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273-280.
8. Coffman RL, Shrader B, Carty J, Mosmann TR, Bond MW. A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization. J Immunol 1987; 139: 3685-3690.
9. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
10. Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988; 168: 543-558
11. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR et al. Regulation of antibody isotype secretion by subsets of antigenspecific helper T cells. Nature 1988; 334: 255-258
12. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173
13. Tada T, Taniguchi M, David CS. Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene(s) that codes for the suppressive T-cell factor in the H-2 histocompatibility complex. J Exp Med 1976; 144: 713-725.
14. Steinmetz M, Minard K, Horvath S, McNicholas J, Srelinger J, Wake C et al. A molecular map of the immune response region from the major histocompatibility complex of the mouse. Nature 1982; 300: 35-42.
15. Kronenberg M, Steinmetz M, Kobori J, Kraig E, Kapp JA, Pierce CW et al. RNA transcripts for I-J polypeptides are apparently not encoded between the I-A and I-E subregions of the murine major histocompatibility complex. Proc Natl Acad Sci USA 1983; 80: 5704-5708
16. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164
17. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184: 387-396
18. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4-CD25- T cell suppressor function. Eur J Immunol 2004; 34: 366-376
19. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M et al. Immunologic self-tolerance maintained by CD25-CD4- naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969-1980
20. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4-CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253
21. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(-)CD25(-) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-1310.
22. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(-)CD25(-) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-1294.
23. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD et al. Human CD4(-)CD25(-) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736-2744
24. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/ suppressive CD4(-)CD25(-) T cells: a highly differentiated and apoptosis-prone population. J Exp Med 2001; 31: 1122-1131
25. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(-)cd4(-) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302
26. Powell BR, Buist NR, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 1982; 100: 731-737
27. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991; 138: 1379-1387
28. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21
29. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73
30. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27: 18-20
31. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4-CD25- regulatory T cells. Nat Immunol 2003; 4: 330-336
32. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061
33. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4- CD25- T regulatory cells. Nat Immunol 2003; 4: 337-342
34. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-341
35. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med 2005; 202: 901-906
36. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 209-226
37. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8- T cell population and induces CD8- CD25- Tregs. J Clin Invest 2005; 115: 2904-2913
38. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4- T reg cells. J Exp Med 2006; 203: 1701-1711
39. Li J, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 2003; 198: 1807-1815
40. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564
41. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3- tumorinfiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18: 3022-3029
42. Kelley TW, Parker CJ. CD4 (-)CD25 (-)Foxp3 (-) regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed) 2010; 2: 980-992
43. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-230
44. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3- regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626-635
45. Betts G, Twohig J, Van den Broek M, Sierro S, Godkin A, Gallimore A. The impact of regulatory T cells on carcinogen-induced sarcogenesis. Br J Cancer 2007; 96: 1849-1854
46. Chamoto K, Wakita D, Ohkuri T, Uchinami Y, Matsushima K, Kitamura H et al. 3- Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy. Cancer Sci 2010; 101: 855-861
47. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010; 70: 7800-7809
48. Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P et al. Cutting edge: depletion of Foxp3- cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009; 183: 7631-7634
49. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8: 191-197
50. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-1346
51. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274
52. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat Rev Immunol 2004; 4: 941-952.
53. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4-CD25- naive T cells to CD4-CD25- regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886
54. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4- T cells. J Immunol 2005; 175: 1483-1490
55. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4- CD25- T regulatory cell activities in lung cancer. Cancer Res 2005; 65: 5211-5220
56. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22: 633-642
57. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 6752-6761.
58. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114: 555-563
59. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012; 72: 5435-5440
60. Lu Y, Giver CR, Sharma A, Li JM, Darlak KA, Owens LM et al. IFN-gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood 2012; 119: 1075-1085
61. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(-) dendritic cells. Int Immunol 2002; 14: 65-68
62. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-1212
63. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12: 870-878
64. Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 2008; 181: 5194-5198
65. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009; 182: 5899-5903
66. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107: 20768-20773
67. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-3198
68. Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007; 21: 353-355
69. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25- T regulatory cells. Blood 2007; 109: 2871-2877
70. Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4-CD25- regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008; 38: 2412-2418
71. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109: E2784-E2793
72. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 2006; 66: 6683-6691
73. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2: 123-128
74. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S et al. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer 2012; 106: 1306-1313
75. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011; 13: R47
76. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402
77. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y et al. Tumor-specific human CD4- regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107-118
78. Sainz-Perez A, Lim A, Lemercier B, Leclerc C. The T-cell receptor repertoire of tumorinfiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 2012; 72: 3557-3569
79. Hindley JP, Ferreira C, Jones E, Lauder SN, Ladell K, Wynn KK et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011; 71: 736-746
80. Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T et al. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol 2010; 184: 6709-6718
81. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194
82. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al. Coexpression of Tim-3 and PD-1 identifies a CD8- T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501-4510
83. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010; 116: 2484-2493
84. Moorman JP, Wang JM, Zhang Y, Ji XJ, Ma CJ, Wu XY et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J Immunol 2012; 189: 755-766
85. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137
86. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265
87. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-2382
88. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993-1002
89. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113: 224-232
90. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009; 30: 102-108.
91. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754.
92. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570
93. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271.
94. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-612
95. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016.
96. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H et al. Intratumor depletion of CD4- cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791
97. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380
98. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949
99. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326-8331
100. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4-CD25- regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98: 1089-1099
101. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3-)/regulatory (FoxP3-) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-1279
102. Fu J, Xu D, Liu Z, ShiM, Zhao P, Fu B et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339
103. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552
104. Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 2009; 33: 490-494
105. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8- tumor-infiltrating lymphocytes and a high CD8-/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-18543
106. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3- T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192
107. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008; 98: 1258-1263
108. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
109. Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P et al. Suppression of tumour-specific CD4(-) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61: 1163-1171
110. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119: 3311-3321.
111. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712
112. Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep 2009; 22: 273-278.
113. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(-)CD4- T-cell subset. Blood 2005; 105: 2877-2886
114. Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6-Foxp3- regulatory T cells in the tumor mass correlates with impaired CD8- T cell function and poor prognosis of breast cancer. Clin Immunol 2010; 135: 466-475
115. Ramos RN, Chin LS, Dos Santos AP, Bergami-Santos PC, Laginha F, Barbuto JA. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4-CD25-Foxp3- regulatory T cells. J Leukoc Biol 2012; 92: 673-682
116. Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res\ 2009; 15: 2166-2173
117. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009; 8: 1930-1934
118. Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 2012; 48: 2004-2011
119. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005-3010.
120. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(-) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J expMed 2001; 194: 823-832
121. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8- mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest 2007; 117: 1902-1913
122. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF et al. Selective depletion of Foxp3- regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70: 7788-7799
123. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419
124. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39: 751-757
125. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118: 5084-5095
126. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132
127. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
128. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
129. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420
130. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060
131. Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012; 2012: 293479.
132. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS ONE 2012; 7: e47077
133. Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PloS ONE 2012; 7: e35981